Tubulis is a biotech company with a focus on the development of innovative therapies for cancer and other diseases.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

BioMedPartners

Seventure Partners

High-Tech Grunderfonds

Bayern Kapital

OCCIDENT

coparion

Andera Partners

Evotec

Fund+

Tubulis GmbH

Today we are presenting full preclinical proof-of-concept data for our two lead candidates TUB-040 and TUB-030 at #AACR2024. 
 
Both candidates consist of an IgG1 antibody attached to its payload, the topoisomerase I inhibitor Exatecan, via a cleavable linker system. TUB-030 targets the tumor-associated antigen 5T4, which covers a broad range of solid tumor indications, while TUB-040 targets Napi2b. This antigen is a well-characterized target in ovarian and lung cancer. The two ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
 
Our data for TUB-030 and TUB-040 show high and durable anti-tumor efficacy in a range of preclinical models as well as superior results in mouse xenograft models when compared to other ADCs targeting the same antigens. Both candidates also have a high predicted human therapeutic index, and we look forward to initiating the first Phase 1/2a clinical trials in 2024.
 
If you missed the poster presentations, you can read more about our ADC candidates in our press release here: https://bwnews.pr/3JbpKp3 

#AACR2024: Meet our CSO Jonas Helma-Smets, CDO Bjoern Hock, and VP Biology & Translational Research Annette Vogl, in San Diego. Come visit our posters on Monday, April 8, 2022, between 1:30 PM and 5:00 PM PT to hear more about Tubulis’ lead candidates TUB-030 and TUB-040. The posters (2622 & 2623) will showcase comprehensive preclinical proof-of-concept results for both candidates in #solidtumors.
 
More information here: https://bit.ly/3SZ5Nq6 

Today marks a pivotal moment in the evolution of Tubulis. We have successfully closed an upsized and oversubscribed €128 million Series B2 #financing co-led by ​EQT Life Sciences​ and Nextech Invest, with participation from new US-based funds, ​Frazier Life Sciences​ and Deep Track Capital, as well as all of our existing investors.

The support of this syndicate of leading global biotech investors underscores the potential of our unique approach to pioneering the next wave of truly differentiated, disease-specific #ADC therapeutics. With this funding, we are well-positioned to advance our next-generation ADCs into clinical evaluation and achieve clinical proof-of-concept for our lead #SolidTumor candidates, TUB-040 and TUB-030. The proceeds will also support the further development of our technology platforms to unlock novel payloads and the establishment of a US subsidiary to expand our corporate footprint.

We look forward to working with ​Christoph Broja​ and ​Kanishka Pothula​ as new members of our Supervisory Board to realize our vision of providing new, high-quality treatment options for many hard-to-treat #cancers.

Read the full PR here: https://bit.ly/3IxICOZ


We will present preclinical proof-of-concept data for our proprietary lead programs, TUB-030 and TUB-040, targeting #SolidTumors at the upcoming American Association for Cancer Research’s Annual Meeting #AACR24.
Our CSO, Jonas Helma-Smets, our CDO, Bjoern Hock, and our VP Biology & Translational Research, Annette Vogl, will be in San Diego, highlighting the preclinical differentiation of our ADC candidates in two poster presentations on April 8, 2024. Both candidates are characterized by disease-tailored composition and high stability, enabling an exceptionally wide therapeutic window. TUB-030 is directed against the #cancer antigen 5T4, expressed in a wide range of solid tumor indications. TUB-040 targets Napi2b, a well-characterized target in ovarian and lung cancer. Both candidates contain a topoisomerase-I-inhibitor as payload and are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
Find more details about the agenda and abstracts in the press release here: https://bit.ly/3SZ5Nq6

Stay tuned to learn more about the full preclinical data, which we will announce in a press release following the presentation at AACR.


COM:TUBULIS

Tubulis

Analysis Not Available